{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:49:46Z","timestamp":1789764586777,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T00:00:00Z","timestamp":1482105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T00:00:00Z","timestamp":1482105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["CP10.12"],"award-info":[{"award-number":["CP10.12"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ipsen Farmaceutica B.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40264-016-0486-x","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T09:41:47Z","timestamp":1482140507000},"page":"153-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Marten A.","family":"Lantinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig M. A.","family":"D\u2019Agnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek F.","family":"Casteleijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie L.","family":"Messchendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J. M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Spithoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Soonawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F. M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zietse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P. H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DIPAK Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P. H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J. M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zietse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,19]]},"reference":[{"issue":"9569","key":"486_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet"},{"issue":"1","key":"486_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2215\/CJN.00080605","volume":"1","author":"KT Bae","year":"2006","unstructured":"Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1(1):64\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"486_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1478-3231.2010.02247.x","volume":"31","author":"L Van Keimpema","year":"2011","unstructured":"Van Keimpema L, De Koning DB, Van Hoek B, et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int. 2011;31(1):92\u20138.","journal-title":"Liver Int."},{"issue":"9","key":"486_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.crad.2005.04.011","volume":"60","author":"TB Larssen","year":"2005","unstructured":"Larssen TB, R\u00f8rvik J, Hoff SR, et al. The occurrence of asymptomatic and symptomatic simple hepatic cysts: a prospective, hospital-based study. Clin Radiol. 2005;60(9):1026\u20139.","journal-title":"Clin Radiol."},{"key":"486_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1750-1172-9-69","volume":"9","author":"WR Cnossen","year":"2014","unstructured":"Cnossen WR, Drenth JP. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis. 2014;9:69.","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"486_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","volume":"10","author":"TJ Gevers","year":"2013","unstructured":"Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10(2):101\u20138.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"10","key":"486_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/liv.12430","volume":"34","author":"TF Wijnands","year":"2014","unstructured":"Wijnands TF, Neijenhuis MK, Kievit W, et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int. 2014;34(10):1578\u201383.","journal-title":"Liver Int."},{"issue":"2","key":"486_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","volume":"63","author":"DC Miskulin","year":"2014","unstructured":"Miskulin DC,\u00a0Abebe KZ,\u00a0Chapman AB, et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014;63(2):214\u201326.","journal-title":"Am J Kidney Dis"},{"issue":"9903","key":"486_CR9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382(9903):1485\u201395.","journal-title":"Lancet."},{"issue":"3","key":"486_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","volume":"63","author":"E Meijer","year":"2014","unstructured":"Meijer E, Drenth JP, d'Agnolo H, et al. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2014;63(3):446\u201355.","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"486_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","volume":"14","author":"M Fleseriu","year":"2011","unstructured":"Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary. 2011;14(2):184\u201393.","journal-title":"Pituitary."},{"issue":"9","key":"486_CR12","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","volume":"27","author":"MC Hogan","year":"2012","unstructured":"Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012;27(9):3532\u20139.","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"486_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/liv.12726","volume":"35","author":"TJ Gevers","year":"2015","unstructured":"Gevers TJ, Hol JC, Monshouwer R, et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int. 2015;35(5):1607\u201314.","journal-title":"Liver Int."},{"issue":"5","key":"486_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/ndt\/gfu227","volume":"30","author":"MA Lantinga","year":"2014","unstructured":"Lantinga MA, Drenth JP, Gevers TJ. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant. 2014;30(5):744\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"486_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2215\/CJN.05380709","volume":"5","author":"A Caroli","year":"2010","unstructured":"Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol. 2010;5(5):783\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"486_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68(1):206\u201316.","journal-title":"Kidney Int."},{"key":"486_CR17","doi-asserted-by":"crossref","unstructured":"van Keimpema L,\u00a0Nevens F,\u00a0Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137(5):1661\u20138 e1\u20132.","DOI":"10.1053\/j.gastro.2009.07.052"},{"issue":"6","key":"486_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1681\/ASN.2009121291","volume":"21","author":"MC Hogan","year":"2010","unstructured":"Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21(6):1052\u201361.","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"486_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","volume":"35","author":"M Chrispijn","year":"2012","unstructured":"Chrispijn M, Nevens F, Gevers TJ, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther. 2012;35(2):266\u201374.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"486_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","volume":"59","author":"M Chrispijn","year":"2013","unstructured":"Chrispijn M, Gevers TJ, Hol JC, et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol. 2013;59(1):153\u20139.","journal-title":"J Hepatol."},{"issue":"4","key":"486_CR21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s10157-014-1047-1","volume":"19","author":"E Higashihara","year":"2015","unstructured":"Higashihara E, Nutahara K, Okegawa T, et al. Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol. 2015;19(4):746\u201352.","journal-title":"Clin Exp Nephrol."},{"issue":"8","key":"486_CR22","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","volume":"90","author":"MC Hogan","year":"2015","unstructured":"Hogan MC, Masyuk T, Bergstralh E, et al. Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin Proc. 2015;90(8):1030\u20137.","journal-title":"Mayo Clin Proc."},{"key":"486_CR23","doi-asserted-by":"crossref","unstructured":"Temmerman F, Ho TA, Vanslembrouck R, et al. Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease. Clin Gastroenterol Hepatol. 2015;13(13):2353\u20139 e1.","DOI":"10.1016\/j.cgh.2015.05.039"},{"issue":"1","key":"486_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000358268","volume":"4","author":"S Treille","year":"2014","unstructured":"Treille S, Bailly JM, Van Cauter J, et al. The use of lanreotide in polycystic kidney disease: a single-centre experience. Case Rep Nephrol Urol. 2014;4(1):18\u201324.","journal-title":"Case Rep Nephrol Urol."},{"issue":"7","key":"486_CR25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2215\/CJN.01870309","volume":"4","author":"M Sall\u00e9e","year":"2009","unstructured":"Sall\u00e9e M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(7):1183\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"486_CR26","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/ndt\/gfu227","volume":"30","author":"MA Lantinga","year":"2015","unstructured":"Lantinga MA, Drenth JP, Gevers TJ. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant. 2015;30(5):744\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"486_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/apt.13047","volume":"41","author":"MA Lantinga","year":"2015","unstructured":"Lantinga MA, Geudens A, Gevers TJ, et al. Systematic review: the management of hepatic cyst infection. Aliment Pharmacol Ther. 2015;41(3):253\u201361.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"486_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5414\/CN108495","volume":"84","author":"MA Lantinga","year":"2015","unstructured":"Lantinga MA, de Sevaux RG, Drenth JP. 18F-FDG PET\/CT during diagnosis and follow-up of recurrent hepatic cyst infection in autosomal dominant polycystic kidney disease. Clin Nephrol. 2015;84(1):61\u20134.","journal-title":"Clin Nephrol"},{"issue":"12","key":"486_CR29","doi-asserted-by":"publisher","first-page":"e0144526","DOI":"10.1371\/journal.pone.0144526","volume":"10","author":"H Kim","year":"2015","unstructured":"Kim H, Park HC, Ryu H, et al. Clinical correlates of mass effect in autosomal dominant polycystic kidney disease. PLoS One. 2015;10(12):e0144526.","journal-title":"PLoS One."},{"issue":"7","key":"486_CR30","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10096-015-2361-6","volume":"34","author":"T Suwabe","year":"2015","unstructured":"Suwabe T, Araoka H, Ubara Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics. Eur J Clin Microbiol Infect Dis. 2015;34(7):1369\u201379.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"3","key":"486_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.20632","volume":"41","author":"R Wiest","year":"2005","unstructured":"Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41(3):422\u201333.","journal-title":"Hepatology"},{"issue":"9","key":"486_CR32","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/gut.30.9.1165","volume":"30","author":"LJ O\u2019Donnell","year":"1989","unstructured":"O\u2019Donnell LJ, Farthing MJ. Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases. Gut. 1989;30(9):1165\u201372.","journal-title":"Gut"},{"issue":"7","key":"486_CR33","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/archinte.1985.00360070158027","volume":"145","author":"DA Parks","year":"1985","unstructured":"Parks DA, Jacobson ED. Physiology of the splanchnic circulation. Arch Intern Med. 1985;145(7):1278\u201381.","journal-title":"Arch Intern Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-016-0486-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:42:05Z","timestamp":1628617325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-016-0486-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,19]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["486"],"URL":"https:\/\/doi.org\/10.1007\/s40264-016-0486-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,19]]},"assertion":[{"value":"19 December 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The DIPAK-1 study is made possible by a grant from the Dutch Kidney Foundation (CP10.12), with Ipsen Farmaceutica B.V., the Netherlands acting as a minor co-sponsor. The Dutch Kidney Foundation and Ipsen had no role in the design or conduct of the study, or in the writing and submission of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marten A. Lantinga, Hedwig M.A. D\u2019Agnolo, Niek F. Casteleijn, Johan W. de Fijter, Esther Meijer, Annemarie L. Messchendorp, Dorien J.M. Peters, Mahdi Salih, Darius Soonawala, Folkert W. Visser, and Jack F.M. Wetzels have no conflicts of interest that are directly relevant to the content of this study. Edwin M. Spithoven has received payment for an Otsuka presentation about the epidemiology of ADPKD and future perspectives. Robert Zietse has received previous grant support from Ipsen. Joost P.H. Drenth has received previous grant support from Ipsen and Novartis. Ron T. Gansevoort holds the rights on the Orphan Designation status of lanreotide for the indication ADPKD, which was granted by the European Medicines Agency (EU\/3\/15\/1514).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}